Skip to content

Study on the safety and effectiveness of active amniotic membrane micro-stents in the treatment of diabetic foot ulcers

Study on the safety and effectiveness of active amniotic membrane micro-stents in the treatment of diabetic foot ulcers

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053260
Enrollment
Unknown
Registered
2021-11-17
Start date
2021-12-01
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic foot ulcer

Interventions

Experimental group:Amniotic Membrane Micro Stent Therapy
Control group:Routine dressing

Sponsors

The First Affiliated Hospital of Naval Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60 years, regardless of gender; 2. Patients diagnosed with diabetic foot ulcer; 3. Chronic ulcer time is longer than 4 weeks and less than 52 weeks; 4. The ulcer is located on the sole or back; 5. The ulcer area is between 2 square centimeters and 8 square centimeters; 6. The affected limb has sufficient blood perfusion. Ankle-brachial index 0.65-1.3, or transcutaneous oxygen partial pressure > 40 mmHg, or Doppler ultrasound shows sufficient blood flow; 7. After debridement, the ulcer wound should be separated from other ulcer edges by at least 2 cm; 8. According to GCP regulations, obtain informed consent and have signed the informed consent form, and volunteer to take the test.

Exclusion criteria

Exclusion criteria: 1. The condition is serious and life-threatening; 2. Severe heart, liver, kidney, lung insufficiency and other diseases; 3. Have mental illness, including severe hysteria, and have no autonomy; 4. Women who are pregnant or breastfeeding, or women who are planning to become pregnant; 5. There are tumors, cancers, etc.; 6. Diseases such as stroke or accompanied by autonomic nerve dysfunction of limbs and skin; 7. Participated in other clinical trials in the last 3 months; 8. According to the researcher's judgment, any medical history that may interfere with the test results or increase the patient's risk; 9. Serious infections such as cellulitis or osteomyelitis.

Design outcomes

Primary

MeasureTime frame
Average wound healing time;

Secondary

MeasureTime frame
Total wound closure rate;Ulcer recurrence rate;Medical fee;

Countries

China

Contacts

Public ContactJi Shizhao

The First Affiliated Hospital of Naval Medical University

shizhaoji@aliyun.com+86 18621583165

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026